Ventilatory outcomes can be achieved with less pressure support

The study indicates that iVAPS improves blood gases as effectively as a standard PS mode, with the added benefit of an overall lower pressure support.¹

iVAPS automatically adjusts the level of pressure support to meet the set alveolar target—providing higher pressure support when required and less when not needed. This automatic response eliminates the problems associated with setting a much higher overall pressure support, which is only needed at limited times during therapy.

iVAPS — making expert titration easy

Research suggests that iVAPS could alleviate some of the complex and time-consuming elements that are required for effective setup of NIV. The findings conclude: “iVAPS is as effective as pressure support initiated by a skilled health care professional in controlling nocturnal hypoventilation. It may facilitate NIV use without extensive prior experience.”¹

iVAPS plays an important role in achieving therapy outcomes for your patients—from setting up patients easily and helping them accept NIV, to keeping them adherent on therapy. Intelligent, automatic and personalized, this advanced technology with an intelligent Back-up Rate (iBR) offers a smart choice for excellence in NIV.

Additional information can be found at ResMed.com/NIV

Every minute counts

ResMed

60 minutes
more

iVAPS
iVAPS makes the difference

Respiratory Care Solutions
Making quality of care easy
60 minutes more with iVAPS: helping overcome challenges in noninvasive ventilation (NIV)—initiation and adherence

Initiating patients on noninvasive ventilation (NIV) can be challenging. Getting them to accept therapy and stay on long-term NIV can be even harder.

iVAPS (intelligent Volume-Assured Pressure Support) can help overcome these challenges.

ResMed’s automatic volume-assurance mode iVAPS is designed for easy set-up and therapy acceptance for patients whose condition is characterized by hypoventilation and likely to change while on therapy. iVAPS is currently available on ResMed’s S9 VPAP™ ST-A and Stellar™ 150.

Patients prefer iVAPS

Evidence from a recent study conducted on patients naive to noninvasive ventilation indicated that when treated with iVAPS, they adhered to therapy for 60 minutes longer (per session) than when treated with standard pressure support (PS) modes. Patients preferred iVAPS, which in turn led to longer use of NIV. The study concluded that iVAPS “may encourage adherence to therapy for patients newly adjusting to NIV.”

Improved gas exchange with prolonged use of NIV

Research shows that prolonged use of NIV is accompanied by long-term improvement in gas exchange and improved response to carbon dioxide in patients with restrictive thoracic disease. By improving therapy adherence, iVAPS may positively influence these outcomes.

ResMed’s volume-assurance mode iVAPS is designed for patients whose condition is characterized by hypoventilation and likely to change while on therapy.
Stellar 150 with iVAPS

60 minutes more

iVAPS makes the difference

Stellar 150 with iVAPS